Retroviral gene therapy in Germany with a view on previous experience and future perspectives
Open Access
- 22 March 2021
- journal article
- review article
- Published by Springer Nature in Gene Therapy
- Vol. 28 (9) , 494-512
Abstract
Gene therapy can be used to restore cell function in monogenic disorders or to endow cells with new capabilities, such as improved killing of cancer cells, expression of suicide genes for controlled elimination of cell populations, or protection against chemotherapy or viral infection. While gene therapies were originally most often used to treat monogenic diseases and to improve hematopoietic stem cell transplantation outcome, the advent of genetically modified immune cell therapies, such as chimeric antigen receptor modified T cells, has contributed to the increased numbers of patients treated with gene and cell therapies. The advancement of gene therapy with integrating retroviral vectors continues to depend upon world-wide efforts. As the topic of this special issue is “Spotlight on Germany,” the goal of this review is to provide an overview of contributions to this field made by German clinical and research institutions. Research groups in Germany made, and continue to make, important contributions to the development of gene therapy, including design of vectors and transduction protocols for improved cell modification, methods to assess gene therapy vector efficacy and safety (e.g., clonal imbalance, insertion sites), as well as in the design and conduction of clinical gene therapy trials.Keywords
This publication has 175 references indexed in Scilit:
- A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial ImmunityScience, 2012
- Alpharetroviral Self-inactivating Vectors: Long-term Transgene Expression in Murine Hematopoietic Cells and Low GenotoxicityMolecular Therapy, 2012
- Insertion Sites in Engrafted Cells Cluster Within a Limited Repertoire of Genomic Areas After Gammaretroviral Vector Gene TherapyMolecular Therapy, 2011
- Biochemical Correction of X-CGD by a Novel Chimeric Promoter Regulating High Levels of Transgene Expression in Myeloid CellsMolecular Therapy, 2011
- Stem-Cell Gene Therapy for the Wiskott–Aldrich SyndromeNew England Journal of Medicine, 2010
- Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemiaNature, 2010
- Efficacy of Gene Therapy for X-Linked Severe Combined ImmunodeficiencyNew England Journal of Medicine, 2010
- Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cellsNature Medicine, 2006
- Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.Proceedings of the National Academy of Sciences, 1994
- Transplantable myeloproliferative disease induced in mice by an interleukin 6 retrovirus.Journal of Experimental Medicine, 1992